0450: Relation of optimized treatment with frequency of hospitalization for cardiac decompensation in patients with chronic heart failure

详细信息    查看全文

• 作者：Amina Asadi ; ^{amina-asadi85@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Fatima Arhlade ; Ichraq Nassiri ; Rachida Habbal
• 刊名：Archives of Cardiovascular Diseases Supplements
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：8
• 期：1
• 页码：29
• 全文大小：46 K

文摘

Heart failure (HF) is a common public health problem. The neurohormonal blockade modifies this natural history; however, it is often suboptimal. Our objective is to appraise the effectiveness of beta blockers and angiotensin-converting enzyme inhibitor (ACEI) in patients with heart failure and to assess at what percentage we used them to treating HF at target doses.

Methods and results

We evaluated medication use in a retrospective cohort of 1841 outpatients followed in therapeutic unit of heart failure for heart failure with reduced ejection fraction. We divided patients on 2 groups: group 1 with cardiac decompensation (n=497, 27%), group 2 with compensated heart failure (n=1344, 73%). The mean age of patients was 65 years with SBP =117.63 in group 1 and 129.4 in group 2, HR =89.3 in group 1, 61.5 bpm in group 2 and sinus rhythm (86.52%). As for treatment, 47% (235/497) in group 1 received a beta-blocker vs 86.75% (1166/1344) in group 2 (p=0.0001) and 85.51% (425/ 497) in group 1 received ACEI vs 88.61% (1191/1344) in group 2 (p=0.34). As for the doses: 6.63% (33/497) in group 1 received an optimal dose of beta-blocker vs 23% (311/1344) in group 2 and 22% (109/497) in group 1 had an optimized dose of ACEI vs 34.44% (463/1344) in group 2 (p=0.0001).

Conclusion

In conclusion, the use of beta blockers and ACEI at target doses is associated with a decreased risk of hospitalization for HF in patients with systolic dysfunction.